After nonfatal myocardial infarction or stroke, initiation of a GLP-1 receptor agonist was linked to reduced risk for all-cause and CV-related mortality in patients with diabetes, researchers reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback